Boronic acid esters and pharmaceutical formulations thereof
Provided herein are boronic acid esters of boronic acid therapeutic agents, such as bortezomib. The boronic acid esters can be used to prepare liposomal formulations of boronic acid therapeutic agents with improved properties, such as enhanced stability. This disclosure, in one aspect, relates to compositions and methods of making and using the compositions.
1. A compound defined by Formula IA
wherein
Z, together with O 1 and O 2 , represent a moiety derived from a polyol, wherein the polyol comprises a sugar;
L is absent, or is a linking group; and
A comprises a lipid moiety chosen from a fatty acid, a glycerolipid, a phospholipid, a sphingolipid, a sterol, or a prenol.
2. The compound of claim 1 , wherein the polyol comprises a monosaccharide.
3. The compound of claim 1 , wherein the polyol comprises a reduced sugar.
4. The compound of claim 1 , wherein the polyol comprises an amino sugar.
5. The compound of claim 1 , wherein the polyol is meglumine, glucamine, mannitol, sorbitol, or fructose.
6. The compound of claim 1 , wherein A is a C 8 -C 40 alkyl group, a C 8 -C 40 alkenyl group, a C 8 -C 40 alkoxy group, a C 8 -C 40 alkylthio group, a C 8 -C 40 alkylsulfinyl group, a C 8 -C 40 alkylsulfonyl group, a C 8 -C 40 alkylamino group, a C 8 -C 40 dialkylamino group, a C 8 -C 40 alkylcarbonyl group, a C 8 -C 40 alkoxycarbonyl group, a C 8 -C 40 alkylaminocarbonyl group, a C 8 -C 40 dialkylaminocarbonyl group, or a moiety defined by the formula below
wherein
the dotted lines indicate that a single or double bond can be present;
R 6 is an alkyl group, an alkenyl group, an alkynyl group, an aryl group, an alkylaryl group, an arylalkyl group, a cycloalkyl group, an alkylcycloalkyl group, a heterocyclyl group, an alkylheterocyclyl group, a heteroaryl group, an alkylheteroaryl group, an alkoxy group, or an alkylthio group; and
R 7 , R 8 , R 9 , R 10 , and R 11 are, independently, hydrogen, a hydroxy group, an amino group, an alkyl group, an alkenyl group, an alkynyl group, an aryl group, an alkylaryl group, an arylalkyl group, a cycloalkyl group, an alkylcycloalkyl group, a heterocyclyl group, an alkylheterocyclyl group, a heteroaryl group, an alkylheteroaryl group, an alkoxy group, an alkylthio group, an alkylsulfinyl group, an alkylsulfonyl group, an alkylamino group, a dialkylamino group, an alkylcarbonyl group, an alkoxycarbonyl group, an alkylaminocarbonyl group, or a dialkylaminocarbonyl group.
7. The compound of claim 1 , wherein the compound is defined by Formula IIA
wherein
X is —O— or —NR 12 —;
R 12 is hydrogen or an alkyl group,
L is absent or is a linking group; and
A comprises a lipid moiety chosen from a fatty acid, a glycerolipid, a phospholipid, a sphingolipid, a sterol, or a prenol.
8. The compound of claim 7 , wherein X is —NH— or —N(CH 3 )—.
9. The compound of claim 1 , wherein the compound is
10. A pharmaceutical formulation comprising
(i) liposomes formed from a vesicle-forming lipid; and
(ii) a compound of claim 1 entrapped in the liposomes.
11. The formulation of claim 10 , wherein the formulation is lyophilized.
12. The formulation of claim 10 , wherein the formulation further comprises a lyoprotectant.
13. A method of treating cancer in a subject comprising administering to the subject a therapeutically effective amount of a compound defined by claim 1 .